Patent US5564068A successfully refreshed from Google Patents.
US5776093A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for imaging and treating organs and tissues
Assignee: Immunomedics Inc
•
Filing: 1992-04-07
•
Granted: 1998-07-07
•
Expires: 2012-04-07
Abstract
Abstract Provided are methods and compositions for detecting and treating normal, hypoplastic, ectopic or remnant tissue, organ or cells in a mammal. The method comprises parenterally injecting a mammalian subject, at a locus and by a route providing access to said tissue or organ, with an composition comprising antibody/fragment which specifically binds to targeted organ, tissue or cell. The antibody/fragment may be administered alone, or labeled or conjugated with an imaging, therapeutic, cytoprotective or activating agent.
Inventors
- 👤 Milton David Goldenberg
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 09:18
CPC Classifications
G; G01; G01R; G01R33/00; G01R33/20; G01R33/44; G01R33/48; G01R33/54; G01R33/56; G01R33/5601; A; A61; A61K; A61K49/00; A61K49/06; A61K49/08; A61K49/10; A61K49/14; A61K49/16; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/10; A61K51/1018; A61K51/1027; A61K51/1036; A61K51/1039; A61K51/1045; A61K51/1057; A61K51/1072; A61P; A61P35/00; A61P37/00; A61P37/02; A61P37/06; A61P43/00; B; B82; B82Y; B82Y5/00; A61K2123/00; Y; Y10; Y10S; Y10S424/00; Y10S424/81; Y10S530/00; Y10S530/868
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
156 words
A method of imaging hypoplastic, anatomically displaced or ectopic cells or tissues in a mammalian subject by scintigraphic or magnetic resonance imaging, comprising the steps of: (a) parenterally injecting a mammalian subject, at a locus and by a route providing access to an organ of interest, with an antibody or antibody fragment which specifically binds a marker produced by or associated with said cell or tissue, said antibody or antibody fragment being labeled with a radioisotope or with a magnetic resonance image enhancing agent capable of external detection, the amount of the labeled antibody or antibody fragment being sufficient to permit a scintigraphic image or an enhanced magnetic resonance image of said organ to be obtained; and (b) obtaining a positive scintigraphic image or positive enhanced magnetic resonance image of said organ, at a time after injection of said agent sufficient for said agent to diffusely accrete in said organ and specifically bind to said marker.
Claim 2
Independent Claim
156 words
A method of imaging hypoplastic, anatomically displaced or ectopic cells or tissues in a mammalian subject by scintigraphic or magnetic resonance imaging, comprising the steps of: (a) parenterally injecting a mammalian subject, at a locus and by a route providing access to an organ of interest, with an antibody or antibody fragment which specifically binds a marker produced by or associated with said cell or tissue, said antibody or antibody fragment being labeled with a radioisotope or with a magnetic resonance image enhancing agent capable of external detection, the amount of the labeled antibody or antibody fragment being sufficient to permit a scintigraphic image or an enhanced magnetic resonance image of said organ to be obtained; and (b) obtaining a positive scintigraphic image or positive enhanced magnetic resonance image of said organ, at a time after injection of said agent sufficient for said agent to diffusely accrete in said organ and specifically bind to said marker.
Claim 3
Dependent Claim
15 words
The method of claim 1, wherein said imaging is used in diagnosis of DiGeorge's syndrome.
Claim 4
Dependent Claim
13 words
The method of claim 1 wherein the isotope emits at 50-1,500 kev energy.
Claim 5
Dependent Claim
23 words
The method of claim 1 wherein the mri enhancing agent is a species of Gadolinium, Iron, Manganese, Rhenium, Europium, Lanthanium, Holmium, or Ferbium.
Claim 6
Dependent Claim
17 words
The method of claim 1, wherein said imaging is used in diagnosis of thymic aplasia or agenesis.
Claim 7
Dependent Claim
23 words
The method of claim 1 wherein the antibody is a Fv, single chain antibody, Fab, Fab', or F(ab') 2 fragment or intact antibody.
Claim 8
Dependent Claim
35 words
The method of claim 1 wherein the antibody or fragment has a specific immunoreactivity to targeted cells or tissues of at least 60 % and a cross-reactivity to other antigens of less than 35 %.
Claim 9
Dependent Claim
18 words
The method of claim 1, wherein said cells or tissues to be imaged are hypoplastic cells or tissues.
Claim 10
Dependent Claim
19 words
The method of claim 1, wherein said cells or tissues to be imaged are anatomically displaced cells or tissues.
Claim 11
Dependent Claim
18 words
The method of claim 1, wherein said cells or tissues to be imaged are ectopic cells or tissues.
Claim 12
Dependent Claim
16 words
The method of claim 10, wherein said cells or tissues to be imaged are endometrial tissues.
Claim 13
Dependent Claim
15 words
The method of claim 1, wherein said imaging is used in diagnosis of juvenile diabetes.
Claim 14
Dependent Claim
99 words
The method of claim 1 wherein the cell or tissue is pretargeted with a first composition comprising a streptavidin-conjugated antibody, biotinylated antibody to be used in conjunction with avidin and biotin, bifunctional antibody, antibody-hapten complexes, or enzyme-conjugated antibody, wherein the antibody is an antibody or antibody fragment which specifically binds a marker produced by or associated with said cell or tissue, and after the first composition accretes at the targeted tissue or cell, a second composition, which bears the imaging principle, is administered which activates the first composition or couples with the first composition to produce a desired effect.
Claim 15
Dependent Claim
60 words
The method of claim 13, wherein the cell or tissue is pretargeted by injecting the subject with the first composition which comprises biotinylated antibody or fragment, optionally injecting the patient with a clearing composition comprising an agent to clear circulating biotinylated antibody or fragment, and then injecting the second composition which comprises biotin conjugated with isotope or mri enhancing agent.
References Cited (Backward Citations)
US3927193A
Cited
US4036945A
Cited
US4331647A
Cited
US4361544A
Cited
US4732864A
Cited
US4859449A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-07-06 | 2002-01-05 | 2002-07-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-07-06 | 2006-01-05 | 2006-07-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-07-06 | 2010-01-05 | 2010-07-07 | $7700.00 | Window Closed / Lapsed |